Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease

• Lawrence S. Honig,
• Marwan N. Sabbagh,
• Christopher H. van Dyck,
• Reisa A. Sperling,
• Steven Hersch,
• Andre Matta,
• Luigi Giorgi,
• Michelle Gee,
• Michio Kanekiyo,
• David Li,
• Derk Purcell,
• Shobha Dhadda,
• Michael Irizarry,
• Lynn Kramer

Affiliations

Lawrence S. Honig

Columbia University Irving Medical Center, NYS Center of Excellence for Alzheimer’s Disease, Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Gertrude H. Sergievsky Center (PH19), & Department of Neurology, Columbia University Vagelos College of Physicians & Surgeons

Marwan N. Sabbagh

Barrow Neurological Institute

Christopher H. van Dyck

Yale School of Medicine

Reisa A. Sperling

Brigham and Women’s Hospital, Massachusetts General Hospital, Harvard Medical School

Steven Hersch

Eisai Inc.

Andre Matta

Eisai Inc.

Luigi Giorgi

Eisai Co., Ltd

Michelle Gee

Eisai Co., Ltd

Michio Kanekiyo

Eisai Inc.

David Li

Eisai Inc.

Derk Purcell

Clario

Shobha Dhadda

Eisai Inc.

Michael Irizarry

Eisai Inc.

Lynn Kramer

Eisai Inc.